Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Papergy Reduction April 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANTS

Application Number

10/809,777

Filing Date

March 24, 2004

First Named Inventor

MUCKE, LENNART

1614 1632

UCAL-280

To Be Assigned

			U.S. PATENT I	OCUMENTS	
Examiner Initials'	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
	110.	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
	 	US-		 	
	-	US-	 	 	
	 -	US-			
		US-	 	 	
	!	US-			
		US-			
-	L	US-			-
		US-			
	<u> </u>	US-			

Art Unit

Examiner Name

Attorney Docket Number

(use as many sheets as necessary)

of

Sheet

		FOREIG	N PATENT DO	CUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials'	No.¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
						<u> </u>
		,				
		_		•		
	<u> </u>					
Examiner Signature		Com		Date Considered	8/4/05	

*EXAMINER: Initiat if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449B/PTO			Complete if Known			
				Application Number	10/809,777		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	March 24, 2004		
				First Named Inventor	MUCKE, LENNART		
				Group Art Unit	1649 /632		
	(use as many sheets	as necessary)	Examiner Name	To Be Assigned		
Sheet	2	of	4	Attorney Docket Number	UCAL-280		

		OTHER ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	Т
D^		Palop et al. (2003) Proc. Natl. Acad. Sci. USA 100:9572-9577	
Dr		Barski et al. (2003) J. Neuroscience 23:3469-3477	
DN.		Moechars et al. (1999) J. Biol. Chem. 274(10):6483-6492	
DN		Mikkonen et al. (1999) Neuroscience 92(2):515-32	
1)1		Ichimiya, et al. (1998) Brain Res. 475, 156-159	
DA		Hof, P. R. & Morrison, J. H. (1991) Exp. Neurol. 111, 293-301	
pr		Baimbridge KG, et al. (1992) Trends Neurosci 15: 303-308	
01		Crabbe et al. (1999) Science 284:1670-1672	
Dr		Wahlsten et al. (2003) J. Neurobiol. 54:283-311	
01		Vig PJS, et al. (2001) Brain Res. Bull. 56:221–225	_
DA		Thorns V, et al, Neuropathology. 2001 Sep;21(3):203-11	
02		Potier B, et al. (1994) Brain Res 661:181–188	

Examiner / 0 //	[But] //	-
Signature Conf. A	Date Considered 8/4/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number

Substitute	e for form 1449B/PTO					Complete If Known	
					Application Number	10/809,777	
ł	INFORMATION DISCLOSURE				Filing Date	March 24, 2004	
l	STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 3 of 4				First Named Inventor	MUCKE, LENNART	
l					Group Art Unit	1644 1632	
					Examiner Name		
Sheet					Attorney Docket Number	UCAL-280	

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T²
muais	NO.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	1
DΆ		Pasti L, et al. (1999) Neuroreport 10:2367-2372	
01		Nägerl UV, et al. (2000) J Neurosci 20:1831–1836	
01		Nägerl UV, and Mody I (1998) J Physiol 509:39-45	
01		Mucke L, et al. (2000) J Neurosci 20:4050-4058	
01		Molinari S, et al. (1996) Proc Natl Acad Sci USA 93:8028-8033	
1/1		Magloczky Z, et al. (1997) Neuroscience 76:377–385	
07		Lledo P-M, et al. (1992) Neuron 9:943-954	
<i>ħ</i>		Klapstein GJ, et al. (1998) Neuroscience 85:361-373	
31		Iritani S, et al, Neuropathology. 2001 Sep;21(3):162-7	
D1		Iacopino AM, and Christakos S (1990) Proc Natl Acad Sci USA 87:4078-4082	
03		Hsia A, et al. (1999) Proc Natl Acad Sci USA 96:3228-3233	
D/I		Heyser CJ, et al. (1997) Proc Natl Acad Sci USA 94:1500-1505	
Dr		Heizmann CW, and Hunziker W (1991) Trends Biochem Sci 16:98–103	

Examiner Signature	No.	Date	8/1/20	
Signature		Considered ·	0)./03	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute	e for form 1449B/PTO				Complete if Known			
				Application Number	10/809,777			
	INFORMATION DISCLOSURE			Filing Date	March 24, 2004			
	STATEMENT BY APPLICANT			First Named Inventor	MUCKE, LENNART			
		•		Group Art Unit	1614 1632			
	(use as many sheets as i	necessar	x)	Examiner Name				
Sheet	4	of	4	Attorney Docket Number	UCAL-280			

	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
DM		Guo Q, et al. (1998) Proc Natl Acad Sci USA 95:3227-3232	
03		Greene JRT, et al. (2001) Neuropathol Appl Neurobiol 27:339–342	
ba		Geula C, et al. (2003) JCompNeurol 455:249-259	
0/1		German DC, et al. (1997) Neuroscience 81:735–743	
0^		Chard PS, et al. (1995) Proc Natl Acad Sci USA 92:5144-5148	
124		Palop et al. "Immunochemical indicators of neuronal and behavioral deficits in transgenic models of Alzheimer's Disease," Abstract 919 (July 20-25, 2002) The 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden	
DM		West, M. J., Coleman, P. D., Flood, D. G. & Troncoso, J. C. (1994) Lancet 344, 769–772	
		·	
			L
			_

Examiner Signature	Due M	Date Considered	8/4/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.